Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04672018
Other study ID # CRO-002-TCM-HTJWT-2019
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 8, 2022
Est. completion date February 2, 2023

Study information

Verified date April 2023
Source University of Karachi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To study the efficacy & safety of Houtou Jianweiling tablet through the non-inferiority clinical trial of Houtou Jianweiling tablet with Omeprazole Enteric-coated tablet in patients with chronic non-atrophic gastritis.


Description:

This is a Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial on the Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date February 2, 2023
Est. primary completion date February 2, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - (1) Comply with the diagnostic criteria for chronic non-atrophic gastritis. - (2) Age between 18 to 65 years. - (3) Voluntarily participate the clinical trials and sign informed consent. Exclusion Criteria: - (1) Subjects with history of gastric surgery. - (2) Patients with complicated and special types of gastritis, peptic ulcer, hemorrhage, cholecystitis, cholelithiasis, dysplasia of gastric mucosa or pathological diagnosis of suspected malignant change. - (3) Patients with atrophy and/or intestinal metaplasia through pathological examination showed;. - (4) Severe primary diseases associated with cardiovascular, cerebrovascular, lung, liver, kidney and hematopoietic system (above grade II of cardiac function; Cr value above the upper limit of normal value), or serious diseases affecting their survival, such as cancer or AIDS; - (5) Patients who have used Chinese and Western medicine to treat chronic non-atrophic gastritis in the last two weeks; - (6) Subjects with psychiatric disorders or a history of alcohol/drug abuse; - (7) Pregnant women, woman who are preparing for pregnancy, lactating women; - (8) Patients who are allergic constitution or allergic to known ingredients of test drugs; - (9) Those who have participated in or are participating in other drug clinical trials in the past 3 months; - (10) The syndrome differentiation is not clear or there are too many and complicated syndromes for the subjects; - (11) Subjects that researchers do not consider appropriate to participate in clinical trials. - (12) Patients with poor compliance are not allowed to participate in this trial. - Those who meet one or more of the above exclusion criteria cannot be included in the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Houtou Jianweiling tablet
Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
Drug:
Omeprazole Tablet
Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.

Locations

Country Name City State
Pakistan Center for Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, university of Karachi Karachi

Sponsors (2)

Lead Sponsor Collaborator
University of Karachi Hunan Xinhui Pharmacy Limited Company

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary The improvement rate of main Clinical symptoms Gastric pain assessment(VAS score): Applying the Visual Analogue Scale (VAS) i.e. 0-10 Numeric Pain Intensity Scale on a 10 cm line segment, 0 is painless, 10 is extremely painful, patients will marked in the corresponding position according to the degree of pain, and the amount of the researcher give a specific score. The grading criteria of gastralgia with VAS score will be, normal: 0 cm; mild: 1-3 cm; moderate: 4-6 cm; severe: 7-10 cm. During the four-week trial period
Primary Physicians Global Assessment to measure quality of life (PGA) Therapeutic efficacy evaluation by primary symptoms i.e. Gastric Distension on 0-6 points scoring system e.g.
0 point: None before treatment or disappeared after treatment 2 points: Slight gastric distension, from time to time, does not affect work and rest.
4 points: Gastric distension can be tolerable, attacks frequently, affecting work and rest.
6 points: The gastric distension is intolerable and persist for a long time. Often needs pain killer to relief pain.
During the four-week trial period
Secondary Laboratory examinations Routine blood tests for liver function (alanine aminotransferase ALT, aspartate aminotransferase AST, gama ?-glutamyltransferase GGT, alkaline phosphatase ALP, total bilirubin T.BIL), Renal Function tests (BUN, Cr) before enrollment and within 5 days after treatment
Secondary Pulse rate measurement The Pulse rate of patients will be measured at different times During the 4 weeks treatment period
Secondary Respiration rate measurement The Respiration rate of patients will be measured at different times During the 4 weeks treatment period
Secondary Blood Pressure measurement Systolic and Diastolic blood pressure of patients will be measured at different times During the 4 weeks treatment period
Secondary Body Temperature measurement The Body Temperature of patients will be measured at different times During the 4 weeks treatment period
Secondary Electrocardiogram ECG QT Interval evaluation before enrollment and within 5 days after treatment
Secondary Stool test for H. Pylori Stool antigen test for H. Pylori detection within 5 days after treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04289519 - Endoscopic Findings of Gastritis in Children
Recruiting NCT02353039 - Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis Phase 2
Recruiting NCT05545397 - Sedation Level on Machine Learning With Electroencephalogram in Painless Gastroenteroscopy Patients
Not yet recruiting NCT05510388 - HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients N/A
Completed NCT02724280 - Linked Color Imaging to Differentiate H. Pylori Associated Gastritis and Gastric Atrophy N/A
Not yet recruiting NCT02961296 - Helicobacter Pylori Antibiotic Susceptibility Testing of Korea N/A
Completed NCT02385045 - i-Scan for the Detection of Helicobacter Pylori N/A
Completed NCT00212225 - Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori) N/A
Not yet recruiting NCT05072938 - Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis Phase 4
Completed NCT02597517 - New Technology to Differentiate Normal Gastric Mucosa From Helicobacter Pylori Associated Gastritis and Gastric Atrophy N/A
Completed NCT02296021 - Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy Phase 4
Completed NCT01576289 - Analysis of Biopsies From the Upper Gastrointestinal Tract N/A
Active, not recruiting NCT03509831 - [KJ-INT-002] BE Study Phase 1
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Suspended NCT04306939 - Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Completed NCT05237115 - Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy Phase 4
Completed NCT02393430 - Clinical Effect of Rebamipide on Chronic Gastritis Phase 4
Completed NCT00579410 - Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule N/A
Completed NCT00267475 - Data Bank for Eosinophilic Disorders N/A
Completed NCT05155072 - Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903 Phase 1